Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595934 | 0.86 | KMT2A (0.78) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL3595931 | 0.86 | KMT2A (0.78) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL16250460 | 0.86 | KMT2A (0.78) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL1886766 | 0.86 | KMT2A (0.78) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL15249477 | 0.86 | KMT2A (0.78) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL4274767 | 0.86 | L3MBTL1 (0.68) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| Hydrochloric Acid SCHEMBL10854308 | 0.85 | KMT2A (0.76) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL3589020 | 0.85 | LMNA (0.81) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL7545873 | 0.83 | L3MBTL1 (0.65) | USP2L3MBTL1KMT2ALMNAOPRK1 | |
| SCHEMBL13915687 | 0.83 | KMT2A (0.63) | USP2L3MBTL1KMT2ALMNAOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | USP2 4773/4885L3MBTL1 4564/4885KMT2A 4652/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | USP2 4848/4885L3MBTL1 4314/4885KMT2A 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.